BCL2 and ovarian carcinoma: To find genetic determinants of ovarian cancer patient resistance to paclitaxel, we studied genomic differences between such patients in the two genes that are targets of paclitaxel, TUBB1, and BCL2.22–25 Our goal was to identify somatic or germline variations in the sequences of these two genes in the two clinical groups with the hope that these variations may correlate with therapy resistance.